Regeneron Pharmaceuticals REGN Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's total current liabilities?
- Regeneron Pharmaceuticals (REGN) reported total current liabilities of $5.11B in Q1 2026.
- How has Regeneron Pharmaceuticals's total current liabilities changed year-over-year?
- Regeneron Pharmaceuticals's total current liabilities increased by 43.2% year-over-year, from $3.57B to $5.11B.
- What is the long-term trend for Regeneron Pharmaceuticals's total current liabilities?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's total current liabilities has grown at a 10.1% compound annual growth rate (CAGR), from $2.7B to $4.37B.
- What does total current liabilities mean?
- The total amount of debt and other obligations due within the next year.
- How do you interpret total current liabilities?
- A rising trend relative to current assets may signal liquidity pressure, whereas a stable or declining trend relative to assets suggests a healthy short-term financial position.
- How does total current liabilities compare across companies?
- Standard liquidity metric used by analysts to compare short-term solvency across the pharmaceutical sector.